|
|
|
|
|
|
|
|
|
 |
|
|
| |
|
Incept BioSystems develops innovative microscale technologies that provide fertility specialists breakthrough capabilities to treat infertility. Our technologies were developed to improve the in vitro manipulation, performance, and viability of high-value cells, and our mission is to set the standard for next-generation clinical devices for the Assisted Reproduction Technology (ART) laboratory.
|
|
|
|
Like many specialized cells, human embryos typically behave much differently while in vitro than they would in the body, and this performance gap can limit their developmental growth and potentially their viability. Incept’s PinFlo™ technology platform is the first to deliver unique control of in vitro cell culture environments so that fertility specialists can offer patients new hope in starting a family. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Doug Powers, Ph.D. HCLD
/ V.P. of Scientific and Clinical Development |
|
|
|
As the Chief Scientific Officer of Boston IVF., Doug Powers has utilized his extensive experience in all phases of IVF practice and management to help grow one of the most commercially successful and largest single private fertility centers in the U.S. Since the clinic’s founding in 1986, Doug has led the scientific and laboratory management of the practice, during which time he has helped parents deliver more than 20,000 IVF babies. He has been responsible for all scientific, financial and personnel decisions in the clinical and research laboratories. He is recognized as having led the laboratory in “firsts” in New England – the first GIFT baby (1986), the first donor egg baby (1991), the first IVF/ICSI baby (1993) and the first cryopreserved oocyte pregnancy (2007). He also led BIVF in all business development related to scientific, research and clinical opportunities. |
| |
|
In a scientific and commercial career that spans nearly 30 years, Doug has been Chairman of the Biology Department at Boston College and is currently on the faculty of Harvard Medical School and is a member of the Harvard Stem Cell Institute. Doug has also been retained as the primary scientific and clinical consultant for a number of early-stage product development projects. . He has been an Investigator on more than 8 FDA clinical trials. Doug received his Ph.D. from the University of Syracuse and completed Post Doctoral Studies in human reproduction at Harvard Medical School. |
|
|
|
Art Gershowitz
/ Director of Research & Development |
|
|
|
Art Gershowitz has over 27 years of experience developing and commercializing a wide array of successful medical device products with a particular expertise in device design, fabrication and assembly methods, project management, and regulatory process management. Most recently he led the R&D of all sterile consumable product groups at Terumo Cardiovascular Systems. |
| |
|
Art’s career has included engineering and management roles at a number of large device firms including Gelman Sciences (now Pall), the Fenwal division of Baxter-Travenol, USCI Division of C.R. Bard, and Terumo Cardiovascular Systems. In that time he has participated in and led the development and launch of products including plasmapheresis systems, angioplasty catheters and guide wire products, and a variety of new or improved sterile devices used in cardiac surgery (oxygenators, catheters, coatings, cardioplegia delivery circuits). Art is a 1978 graduate of the University of Michigan where he received his BS in Chemical Engineering. |
|
|
|
Gary D. Smith, Ph.D. HCLD
/ Co-Founder |
|
|
|
Director of Human Reproduction, Departments of Obstetrics and Gynecology, Urology, and
Molecular and Integrated Physiology, University of Michigan. |
|
|
|
Gary D. Smith is
the director of the Assisted Reproductive Technologies Laboratory in
the University of Michigan Medical Center as well as the Fertility
Counseling and Gamete Cryopreservation Program in the Comprehensive
Cancer Center at Michigan. His efforts are focused on developing new,
and improving existing, laboratory methods of treating or preventing
infertility. Since 1995, Dr. Smith has been an invited lecturer around
the world for his work in egg, embryo, and stem cell biology. Basic and
translational science research in his laboratory is sponsored by the
National Institutes of Health, United States Department of Agriculture,
and the Lance Armstrong Foundation. Dr. Smith serves as the interim
Chief Science Officer and works closely with Dr. Takayama on all design
issues relating to Incept's IVF clinic applications. |
|
|
|
Shuichi Takayama, Ph.D.
/ Co-Founder |
|
|
|
Department
of Biomedical Engineering, Macromolecular Science and Engineering,
University of Michigan. |
|
|
|
Shuichi Takayama
received his M.S. from the University of Tokyo in 1994 and his Ph.D.
degree in chemistry from the Scripps Research Institute in 1998, after
which he joined the G.M. Whitesides group at Harvard University as a
Leukemia and Lymphoma Society postdoctoral fellow. He has received the
The Ralph E. Powe Junior Faculty Award (ORAU, 2002), and The NSF Career
Award (NSF, 2003). Dr. Takayama’s work has been instrumental
in developing the PinFlo Controller and designing and testing the all
current microcirculatory chip technology. Dr. Takayama serves as the
Chief Technology Officer and leads early stage product research
programs. |
|
|
|
|
|
|
|
|
|
|
back to top
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Tom Porter has a broad range of experience in founding,
managing and advising successful technology growth companies. He
co-founded and is a General Partner Emeritus in EDF Ventures®,
an Ann Arbor, Michigan-based venture capital firm investing in early
stage market driven companies in health care and information
technology. He led the health care practice at EDF where he co-founded
five health care companies and often served as interim Chief Executive
Officer during the formative stages of the companies. He currently
serves as a Director IntraLase Corp. (NASDAQ: ILSE), a developer of
next-generation lasers for ophthalmic refractive surgery, one of the
companies he co-founded. He previously has held Board positions for
numerous health care and software companies. |
|
|
| His previous
experience includes serving as President and Chief Executive Officer of
Environmental Research Group, Inc., which he helped build to be one of
the nation's leading environmental monitoring firms. Tom has also held
various marketing management positions in Procter & Gamble and
other consumer products companies. He was a Mentor for the Kauffman
Foundation's Venture Capital Fellows Program and chaired both the
Michigan Governor's Committee for Recruiting and Retaining High Tech
Talent to Michigan and the Governor's Life Science Corridor Task Force |
|
|
| Tom holds an MBA
degree from the University of Michigan where he is Adjunct Professor
and Entrepreneur-In-Residence. His bachelor’s degree is from
DePauw University where he also serves as a Director of the McDermond
Management Center.
|
|
|
|
John E.
Osborn, Senior Vice President, General Counsel &
Secretary with Cephalon, Inc., a leading biopharmaceutical company with
its principal offices located in suburban Philadelphia, where he has
been responsible for all legal, intellectual property, government
affairs, public affairs and quality assurance matters. From 1992 to
1997 he held various positions with The DuPont Merck Pharmaceutical
Company, including Vice President & Associate General Counsel.
In 1989, he was appointed Special Assistant to the Legal Adviser of the
U.S. Department of State, where he served for three years. Prior to
that, he practiced corporate law with Hale and Dorr in Boston, clerked
for Judge Albert V. Bryan of the U.S. Court of Appeals for the Fourth
Circuit, and worked on Capitol Hill for Congressman Jim Leach and the
late Senator John Heinz. |
|
|
|
John studied at
the College of William & Mary and graduated from The University
of Iowa, where he was elected to Phi Beta Kappa. He completed graduate
work in international affairs at Johns Hopkins and Princeton, and
earned his law degree at the University of Virginia. |
|
|
|
Jim Adox, Venture Investors of Wisconsin, Jim joined Venture Investors in 2007 as a Managing Director of Venture Investors LLC, and heads up the firm’s Ann Arbor, Michigan office. He focuses on the firm’s Information Technology practice, works with the Venture Investors Health Care Managing Directors on medical device investments, and is the primary contact for all deals in Michigan for the firm. |
|
|
|
Prior to Venture Investors, Jim formed RidgeLine Ventures, where he helped co-found university spin-outs and advised early stage companies, including Tissue Regeneration Systems and RhinoLight (Allux Medical). Prior to RidgeLine, Jim was a Partner at EDF Ventures. During his tenure at EDF, he led the spin-out, sourcing, financing, syndication and exit of many EDF portfolio companies. Jim served on the Board of Directors of Avail Networks and HandyLab and was responsible for additional portfolio companies, serving as a board observer for Alfalight, Ardesta, TherOx, and Xtera Communications. |
|
|
|
Jim has over nine years experience in various operating and strategic roles. His technical experience includes six years of design and development engineering, product development, project management, testing and manufacturing for leading U.S. corporations. He spent two years in international sales, marketing and business development, where he had P & L responsibility for product launches in Brazil, Mexico and Argentina. He also co-led the successful $50MM acquisition and integration of a competitor in Argentina. |
|
|
|
Jim earned a Bachelor of Science in Mechanical Engineering, a Master of Science in Mechanical Engineering, and a Master of Business Administration with High Distinction – all from the University of Michigan. |
|
|
|
|
|
|
|
|
|
|
back to top
|
|
|
|
|
|
